Technical Snapshots for These Generic Drugs Stocks -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and Lannett

NEW YORK, September 5, 2017 /PRNewswire/ --

If you want a Stock Review on CPRX, FLXN, SUPN, or LCI then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Today, DailyStockTracker.com shifts focus on Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Flexion Therapeutics Inc. (NASDAQ: FLXN), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), and Lannett Co. Inc. (NYSE: LCI). According to a Research and Markets report, the US is the biggest generic drugs market in the world. In fact, nearly 80% of the prescriptions written in the US are for generic drugs. Access DailyStockTracker.com's complimentary reports for today's stocks line-up at:

http://dailystocktracker.com/register/

Catalyst Pharmaceuticals 

Florida-based Catalyst Pharmaceuticals Inc.'s stock finished last Friday's session 4.73% lower at $2.62. A total volume of 1.15 million shares was traded, which was above their three months average volume of 929,070 shares. The Company's shares have advanced 10.08% over the previous three months and 149.52% since the start of this year. The stock is trading above its 200-day moving average by 41.89%. Additionally, shares of Catalyst Pharma, which focuses on the development and commercialization of therapies for people with rare debilitating diseases, have a Relative Strength Index (RSI) of 40.58.

On August 30^th, 2017, Catalyst Pharma provided an update on the status of its Firdapse® (amifampridine phosphate) development activities. Patrick J. McEnany, CEO, stated: "We are pleased to report that we have reached an agreement with the FDA under a Special Protocol Assessment for the trial design, clinical endpoints and statistical analysis approach for our Phase 3 clinical trial evaluating Firdapse for the treatment of patients with MuSK antibody positive Myasthenia Gravis (MuSK-MG)." Visit us today and access your complete report on CPRX for free at:

http://dailystocktracker.com/registration/?symbol=CPRX

Flexion Therapeutics 

On Friday, shares in Massachusetts headquartered Flexion Therapeutics Inc. ended the session 6.23% lower at $24.10. The stock recorded a trading volume of 831,067 shares, which was higher than its three months average volume of 542,560 shares. The Company's shares have gained 9.50% in the last one month, 40.44% in the previous three months, and 26.71% on an YTD basis. The stock is trading 5.79% above its 50-day moving average and 15.62% above its 200-day moving average. Moreover, shares of Flexion Therapeutics have an RSI of 54.81.

On August 24^th, 2017, research firm Northland Capital initiated an 'Outperform' rating on the Company's stock.

On August 30^th, 2017, Flexion Therapeutics announced that Michael Clayman, M.D., President and CEO, will participate in an analyst-led fireside chat at the 2017 Wells Fargo Healthcare Conference on September 06^th, 2017, at 9:40am ET at the Westin Waterfront Hotel in Boston, Mass. The live webcast and subsequent archived recording of the presentation may be accessed on the Company's website. The complimentary research report on FLXN can be accessed at:
http://dailystocktracker.com/registration/?symbol=FLXN

Supernus Pharmaceuticals 

Maryland-based Supernus Pharmaceuticals Inc.'s ("SUPN") shares jumped 3.49%, closing the session at $47.40. A total volume of 787,660 shares was traded, which was above their three months average volume of 635,840 shares. The stock has surged 13.67% in the last one month, 21.38% over the previous three months, and 87.72% on an YTD basis. The Company's shares are trading 10.16% and 45.80% above their 50-day and 200-day moving averages, respectively. Additionally, shares of Supernus Pharma have an RSI of 63.57.

On August 15^th, 2017, SUPN announced that, following a four-day bench trial, the US District Court for the District of New Jersey ruled that TWi Pharmaceuticals, Inc. and its subsidiary infringed US Patent Nos. 7,722,898, 7,910,131, and 8,821,930 by submitting to the FDA an Abbreviated New Drug Application seeking permission to market a generic version of Oxtellar XR® before the expiration of SUPN's patents. The District Court ruling also confirmed the validity of US Patent Nos. 7,722,898, 7,910,131, and 8,821,930. Register for free on DailyStockTracker.com and download the research report on SUPN at: http://dailystocktracker.com/registration/?symbol=SUPN

Lannett 

Last Friday at the close, shares in Pennsylvania-based Lannett Co. Inc. recorded a trading volume of 365,971 shares. The stock ended the session 0.85% higher at $17.70. The Company's shares have advanced 2.61% in the past month. The stock is trading below its 50-day moving average by 6.57%. Furthermore, shares of Lannett, which develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the US, have an RSI of 53.20.

On August 23^rd, 2017, Lannett reported financial results for its Q4 FY17 ended June 30^th, 2017. For Q4 FY17, total net sales were $139.1 million and gross profit was $58.9 million. For the quarter, R&D expenses were $11.4 million; SG&A expenses were $16.5 million; acquisition and integration-related expenses were $0.3 million; and restructuring expenses were $1.8 million. Get free access to your research report on LCI at:

http://dailystocktracker.com/registration/?symbol=LCI

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com